KR20220145826A - 펩티드 화합물 및 이를 이용한 질병의 치료 방법 - Google Patents

펩티드 화합물 및 이를 이용한 질병의 치료 방법 Download PDF

Info

Publication number
KR20220145826A
KR20220145826A KR1020227028077A KR20227028077A KR20220145826A KR 20220145826 A KR20220145826 A KR 20220145826A KR 1020227028077 A KR1020227028077 A KR 1020227028077A KR 20227028077 A KR20227028077 A KR 20227028077A KR 20220145826 A KR20220145826 A KR 20220145826A
Authority
KR
South Korea
Prior art keywords
peptide
group
seq
isolated peptide
proline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227028077A
Other languages
English (en)
Korean (ko)
Inventor
에란 오바디아
아비 벤-시몬
일라나 코헨
Original Assignee
이뮤니티 파르마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤니티 파르마 엘티디. filed Critical 이뮤니티 파르마 엘티디.
Publication of KR20220145826A publication Critical patent/KR20220145826A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020227028077A 2020-01-15 2021-01-14 펩티드 화합물 및 이를 이용한 질병의 치료 방법 Pending KR20220145826A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same
IL272074 2020-01-15
PCT/IL2021/050044 WO2021144798A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same

Publications (1)

Publication Number Publication Date
KR20220145826A true KR20220145826A (ko) 2022-10-31

Family

ID=76863930

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028077A Pending KR20220145826A (ko) 2020-01-15 2021-01-14 펩티드 화합물 및 이를 이용한 질병의 치료 방법

Country Status (12)

Country Link
US (1) US20230049549A1 (enExample)
EP (1) EP4090347A1 (enExample)
JP (1) JP7809060B2 (enExample)
KR (1) KR20220145826A (enExample)
CN (6) CN119708144A (enExample)
AU (1) AU2021207415A1 (enExample)
BR (1) BR112022013978A2 (enExample)
CA (1) CA3167139A1 (enExample)
CO (1) CO2022011101A2 (enExample)
IL (1) IL272074B2 (enExample)
MX (1) MX2022008746A (enExample)
WO (1) WO2021144798A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280101B2 (en) 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
WO2003037172A2 (en) * 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
AU2005276117C1 (en) * 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
US8648045B2 (en) * 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
US20130096070A1 (en) * 2009-04-07 2013-04-18 University Of Kansas Peptide targeting of inner ear cells
CA2836503C (en) * 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
BR112017022845A2 (pt) * 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
IL280101B2 (en) * 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Also Published As

Publication number Publication date
MX2022008746A (es) 2022-10-13
WO2021144798A1 (en) 2021-07-22
CN119708141A (zh) 2025-03-28
JP7809060B2 (ja) 2026-01-30
CN115942948A (zh) 2023-04-07
CA3167139A1 (en) 2021-07-22
EP4090347A1 (en) 2022-11-23
US20230049549A1 (en) 2023-02-16
CN119708142A (zh) 2025-03-28
CO2022011101A2 (es) 2022-11-08
AU2021207415A1 (en) 2022-09-08
CN119708144A (zh) 2025-03-28
JP2023510019A (ja) 2023-03-10
IL272074B2 (en) 2024-12-01
CN119708143A (zh) 2025-03-28
IL272074A (en) 2021-07-29
CN115942948B (zh) 2025-01-14
BR112022013978A2 (pt) 2022-10-11
CN119708140A (zh) 2025-03-28
IL272074B1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US10040836B2 (en) Peptides for the treatment of neurodegenerative diseases
US20240190919A1 (en) Peptide compounds and therapeutic uses of same
EP2478009B1 (en) Peptides for the treatment of oxidative stress related disorders
US20140045764A1 (en) Neuroprotective peptides
US20230212261A1 (en) Isolated polypeptides of cd44 and uses thereof
KR20220145826A (ko) 펩티드 화합물 및 이를 이용한 질병의 치료 방법
EP1896496B1 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
RU2843553C2 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение
US20110092448A1 (en) Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
EP3464322B1 (en) Novel molecules for the treatment of inflammation
US6849601B1 (en) Peptides
US20180193409A1 (en) Peptidyl tpor antagonists and uses thereof
US20110306561A1 (en) COMPLEMENT C3a DERIVED DIMERIC PEPTIDES AND USES THEREOF
US20230127559A1 (en) Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902